⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27682261 | 0.78 | — | — | |
| SCHEMBL1822712 | 0.78 | — | — | |
| SCHEMBL19155961 | 0.74 | — | — | |
| SCHEMBL14608776 | 0.74 | — | — | |
| SCHEMBL21282875 | 0.74 | — | — | |
| SCHEMBL10859946 | 0.74 | — | — | |
| SCHEMBL12618144 | 0.74 | — | — | |
| SCHEMBL2493536 | 0.74 | — | — | |
| SCHEMBL29951491 | 0.72 | CA2 (0.32) | — | |
| SCHEMBL29504006 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023114954-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
| EP-2519522-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2519522-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8501770-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501770-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501770-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2013078254-A1 | BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-8440702-B2 | 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2029560-B1 | 1,3-OXAZOLIDIN-2-ONE DERIVATIVES USEEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20100087649-A1 | QUINOLINONE DERIVATIVES | TIBOTEC BVBA (BE) | 2010-04-08 | — | — | US | disclosed |
| US-20100087649-A1 | QUINOLINONE DERIVATIVES | TIBOTEC BVBA (BE) | 2010-04-08 | — | — | US | disclosed |
| WO-2008037784-A1 | QUINOLINONE DERIVATIVES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-03 | — | — | WO | disclosed |
| EP-0974602-B1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR CORP (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6291596-B1 | CONTACTING OLEFINICALLY UNSATURATED COMPOUND WITH HYDROGEN IN THE PRESENCE OF A HYDROGENATION CATALYST COMPRISING TITANIUM OR ZIRCONIUM OR HAFNIUM COMPOUND IN AN INERT, ORGANIC SOLVENT | JSR CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0974602-A1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR Corporation (JP) | 2000-01-26 | — | — | EP | disclosed |
| EP-0063736-A2 | Use of dihydroxy pyridines as couplers in oxidation hair dyes, and hair dyeing preparation | Henkel Kommanditgesellschaft auf Aktien (DE) | 1982-11-03 | — | — | EP | disclosed |